Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2008

View Archived Issues

BMD increased by percutaneous injection of novel GEM-OS2 in preclinical studies

Bone formation enhanced with GSK's calcium-sensing receptor antagonist ronacaleret

New agents for diabetic nephropathy disclosed in recent Kowa patent

Recent Wyeth patent reports novel bazedoxifene prodrugs

AEterna completes enrollment in phase III study of LHRH antagonist cetrorelix in BPH

Boehringer and Evec sign license agreement for fully human therapeutic antibody program

Athera and Dyax sign collaboration agreement for antibodies in cardiovascular inflammation

Calabar initiates phase II study of Xalieve in xerostomia

AEterna initiates second stage of patient recruitment in phase II ovarian cancer trial of AEZS-108

Novel agents for cardiovascular disorders described in recent patent literature

deCODE files IND for DG-071 for Alzheimer's disease and other cognitive disorders

Genentech, Roche and Glycart sign development agreement for monoclonal antibody GA-101

Genentech reports case of PML in patient who received Raptiva for more than 4 years

Crucell receives contract from NIAID to advance Ebola and Marburg vaccines

DSMB recommends continuation of BioMS Medical's MAESTRO-03 trial of dirucotide in MS

Lilly and Deciphera sign agreement for B-Raf kinase inhibitors for cancer treatments

Astellas launches Irribow in Japan for diarrhea-predominant IBS

CombinatoRx reports top-line results from phase IIb Synavive study

Dendreon presents interim data from phase III Provenge trial

PDC Biotech reports progress on preclinical program for PDC-31

Rifaximin achieves significant results in prevention of hepatic encephalopathy

Unigene initiates phase I study for oral PTH

Lilly to acquire ImClone Systems

R&D highlights from the UBS Global Life Sciences Conference in New York: Vectura Group

Novel pharmacological chaperones identified as promising agents to treat phenylketonuria

Adjuvant therapy with catumaxomab safe in phase II gastric cancer study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...